Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Sees Large Increase in Short Interest

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCYGet Free Report) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 36,800 shares, an increase of 1,500.0% from the December 15th total of 2,300 shares. Based on an average trading volume of 214,500 shares, the short-interest ratio is currently 0.2 days.

Chugai Pharmaceutical Price Performance

Shares of OTCMKTS:CHGCY opened at $21.48 on Wednesday. Chugai Pharmaceutical has a 1 year low of $14.52 and a 1 year high of $26.00. The company has a market cap of $70.69 billion, a P/E ratio of 27.54 and a beta of 0.81. The stock’s fifty day moving average price is $21.96 and its 200-day moving average price is $22.30.

Chugai Pharmaceutical Company Profile

(Get Free Report)

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

Further Reading

Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.